FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956564433> ?p ?o ?g. }

• W2956564433 endingPage "328" @default.
• W2956564433 startingPage "328" @default.
• W2956564433 abstract "Celecoxib (CLX), a selective COX-2 inhibitor, is a biopharmaceutics classification system (BCS) class II drug with its bioavailability being limited by thepoor aqueoussolubility. The purpose of this study was to develop and optimize CLX nanocrystalline(CLX-NC) solid dispersion prepared by the wet medium millingtechnique combined with lyophilizationto enhance oral bioavailability. In formulation screening, the resulting CLX-NC usingpolyvinylpyrrolidone (PVP) VA64 and sodiumdodecyl sulfate (SDS) as combined stabilizers showed the minimum particle size and a satisfactory stability. The formulation and preparation processwere further optimized by central composite experimentaldesign with PVP VA64 concentration (X1), SDS concentration (X2) and milling times (X3) as independent factors and particle size (Y1), polydispersity index (PDI, Y2) and zeta potential (Y3) as response variables. The optimal condition was determined as a combination of 0.75% PVP VA64, 0.11% SDS with milling for 90 min.The particle size, PDI and zeta potential of optimized CLX-NC were found to be 152.4 ± 1.4 nm, 0.191 ± 0.012 and −34.4 ± 0.6 mV, respectively. The optimized formulation showed homogeneous rod-like morphology as observed by scanning electron microscopy and was in a crystalline state as determined by differential scanning calorimetry and powder X-ray diffraction. In a storage stability study, optimized CLX-NC exhibited an excellent physical stability during six months’ storage at both the refrigeration and room conditions. In vivo pharmacokinetic research in Sprague-Dawley ratsdisplayed that Cmax and AUC0–∞ of CLX-NC were increased by 2.9 and 3.1 fold, compared with physical mixture. In this study, the screening and optimizing strategy of CLX-NC formulation represents a commercially viable approach forenhancing the oral bioavailability of CLX." @default.
• W2956564433 created "2019-07-23" @default.
• W2956564433 creator A5010582470 @default.
• W2956564433 creator A5022263793 @default.
• W2956564433 creator A5042152032 @default.
• W2956564433 creator A5063468498 @default.
• W2956564433 creator A5076284332 @default.
• W2956564433 creator A5077876461 @default.
• W2956564433 date "2019-07-11" @default.
• W2956564433 modified "2023-10-02" @default.
• W2956564433 title "Enhanced Oral Bioavailability of Celecoxib Nanocrystalline Solid Dispersion based on Wet Media Milling Technique: Formulation, Optimization and In Vitro/In Vivo Evaluation" @default.
• W2956564433 cites W1576568858 @default.
• W2956564433 cites W1787393235 @default.
• W2956564433 cites W1853947313 @default.
• W2956564433 cites W2000924336 @default.
• W2956564433 cites W2028724994 @default.
• W2956564433 cites W2037803874 @default.
• W2956564433 cites W2039256326 @default.
• W2956564433 cites W2047393407 @default.
• W2956564433 cites W2047698253 @default.
• W2956564433 cites W2049599102 @default.
• W2956564433 cites W2053334003 @default.
• W2956564433 cites W2054260281 @default.
• W2956564433 cites W2056211275 @default.
• W2956564433 cites W2059225643 @default.
• W2956564433 cites W2088563332 @default.
• W2956564433 cites W2091357955 @default.
• W2956564433 cites W2105502591 @default.
• W2956564433 cites W2132081026 @default.
• W2956564433 cites W2132471086 @default.
• W2956564433 cites W2400986352 @default.
• W2956564433 cites W2591169316 @default.
• W2956564433 cites W2606438496 @default.
• W2956564433 cites W2607137320 @default.
• W2956564433 cites W2772974777 @default.
• W2956564433 cites W2773263270 @default.
• W2956564433 cites W2783618712 @default.
• W2956564433 cites W2792200797 @default.
• W2956564433 cites W2792793009 @default.
• W2956564433 cites W2888025890 @default.
• W2956564433 cites W2897161638 @default.
• W2956564433 cites W2923435777 @default.
• W2956564433 cites W2981727380 @default.
• W2956564433 cites W657638685 @default.
• W2956564433 doi "https://doi.org/10.3390/pharmaceutics11070328" @default.
• W2956564433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6680726" @default.
• W2956564433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31336734" @default.
• W2956564433 hasPublicationYear "2019" @default.
• W2956564433 type Work @default.
• W2956564433 sameAs 2956564433 @default.
• W2956564433 citedByCount "38" @default.
• W2956564433 countsByYear W29565644332019 @default.
• W2956564433 countsByYear W29565644332020 @default.
• W2956564433 countsByYear W29565644332021 @default.
• W2956564433 countsByYear W29565644332022 @default.
• W2956564433 countsByYear W29565644332023 @default.
• W2956564433 crossrefType "journal-article" @default.
• W2956564433 hasAuthorship W2956564433A5010582470 @default.
• W2956564433 hasAuthorship W2956564433A5022263793 @default.
• W2956564433 hasAuthorship W2956564433A5042152032 @default.
• W2956564433 hasAuthorship W2956564433A5063468498 @default.
• W2956564433 hasAuthorship W2956564433A5076284332 @default.
• W2956564433 hasAuthorship W2956564433A5077876461 @default.
• W2956564433 hasBestOaLocation W29565644331 @default.
• W2956564433 hasConcept C11432220 @default.
• W2956564433 hasConcept C120665830 @default.
• W2956564433 hasConcept C121332964 @default.
• W2956564433 hasConcept C127413603 @default.
• W2956564433 hasConcept C13965031 @default.
• W2956564433 hasConcept C147789679 @default.
• W2956564433 hasConcept C155672457 @default.
• W2956564433 hasConcept C171250308 @default.
• W2956564433 hasConcept C177562468 @default.
• W2956564433 hasConcept C178790620 @default.
• W2956564433 hasConcept C181389837 @default.
• W2956564433 hasConcept C185592680 @default.
• W2956564433 hasConcept C187530423 @default.
• W2956564433 hasConcept C192562407 @default.
• W2956564433 hasConcept C22979827 @default.
• W2956564433 hasConcept C39519442 @default.
• W2956564433 hasConcept C42360764 @default.
• W2956564433 hasConcept C43617362 @default.
• W2956564433 hasConcept C71924100 @default.
• W2956564433 hasConcept C86181022 @default.
• W2956564433 hasConcept C97355855 @default.
• W2956564433 hasConcept C98274493 @default.
• W2956564433 hasConceptScore W2956564433C11432220 @default.
• W2956564433 hasConceptScore W2956564433C120665830 @default.
• W2956564433 hasConceptScore W2956564433C121332964 @default.
• W2956564433 hasConceptScore W2956564433C127413603 @default.
• W2956564433 hasConceptScore W2956564433C13965031 @default.
• W2956564433 hasConceptScore W2956564433C147789679 @default.
• W2956564433 hasConceptScore W2956564433C155672457 @default.
• W2956564433 hasConceptScore W2956564433C171250308 @default.
• W2956564433 hasConceptScore W2956564433C177562468 @default.
• W2956564433 hasConceptScore W2956564433C178790620 @default.
• W2956564433 hasConceptScore W2956564433C181389837 @default.
• W2956564433 hasConceptScore W2956564433C185592680 @default.

• next